NGLFINE2,701.00

NGL Fine-Chem Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersSYNCOMFJAGSNPHARMHESTERBIOAMRUTANJANWINDLASINDOCOSAIPARENTMcap ₹1,669 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations338.7368.3501.0536.2
Other Income14.18.614.716.6
Total Income352.8376.9515.7552.7
Expenses
+ Cost of Materials Consumed170.8182.4247.2272.4
+ Changes in Inventories-12.1-0.0-7.7-23.3
+ Employee Benefit Expense45.155.565.568.7
+ Finance Costs1.32.34.54.2
+ Depreciation & Amortisation11.612.519.620.6
+ Other Expenses81.696.4123.3134.2
Total Expenses298.4349.2452.3476.8
EBITDA53.333.972.784.2
EBIT41.621.453.163.6
Profit
PBT before Exceptional Items54.427.763.475.9
Pretax Income54.427.763.475.9
+ Current Tax12.26.216.119.2
+ Deferred Tax0.90.4-0.8-0.5
Tax Expense13.16.615.218.7
Net Income41.321.148.157.2
+ Net Income — Continuing Ops41.321.148.157.2
+ Other Comprehensive Income-0.2-0.2-0.2-0.4
Total Comprehensive Income41.220.947.956.8
Per Share
Basic EPS66.8834.1977.9092.59
Diluted EPS66.8834.1977.9092.59
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.2-0.2-0.4
+ Items NOT to be Reclassified to P&L-0.3
+ Tax on Items NOT to be Reclassified0.3-0.1-0.4
+ Tax on Items NOT to be Reclassified — alt tag0.2
+ Tax on Items to be Reclassified-0.1
+ Tax on Items to be Reclassified — alt tag-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations66.8834.1977.9092.59
Diluted EPS — Continuing Operations66.8834.1977.9092.59
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit180.0185.9261.5287.1
Gross Margin %53.1550.4752.1953.54
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)54.427.763.475.9
Net Income Adj (tax-effected)41.321.148.157.2
EPS Adj66.8834.1977.9092.59
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.005.005.005.00
Filed Debt Equity0.00
Filed Dscr0.00
Filed Iscr0.13
Paid Up Equity Capital3.13.13.13.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.